Anibal Arce Medina

Anibal Arce Medina

Auto-generated profile, based on publicly available information

Anibal Arce Medina

Pontificia Universidad Católica de Chile

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2025 in ACS Synthetic Biology
Verified
Journal Article
Closed access
DBDylan M. Brown
Dylan M. Brown
DPDaniel A. Phillips
Daniel A. Phillips
DGDavid C. Garcia
David C. Garcia
AAAnibal Arce
Anibal Arce
TLTyler Lucci
Tyler Lucci
JLJulius B. Lucks
Julius B. Lucks

20 February 2021 in medRxiv
Verified
Preprint
Open access
PDF file
ABAli Bektaş
Ali Bektaş
MCMichael Covington
Michael Covington
GAGuy Aidelberg
Guy Aidelberg
AAAnibal Arce
Anibal Arce
TMTamara Matute
Tamara Matute
AJAnitha Jayaprakash
Anitha Jayaprakash
The COVID-19 pandemic has highlighted bottlenecks in large-scale, frequent testing of populations for infections. PCR-based diagnostic tests are expensive, reliant on expensive centralized labs, can take days to deliver results, and are prone to backlogs and supply shortages. Antigen tests, that bind and detect the surface proteins of a virus, are rapid and inexpensive but suffer from high false negative rates. To address this problem, we have created an inexpensive, simple, and robust 60-minute Do-It-Yourself (DIY) workflow to detect viral RNA from nasal swabs or saliva with high sensitivity (0.1 to 2 viral particles/ µ l) and specificity (>97% True Negative Rate) utilizing reverse transcription loop-mediated isothermal amplification (RT-LAMP). Our workflow, ALERT (Accessible LAMP-Enabled Rapid Test), incorporates the following features: 1) Increased shelf-life and ambient temperature storage by using wax layers to isolate enzymes from reaction, 2) Improved specificity by using sequence-specific QUASR reporters, 3) Increased sensitivity through use of a magnetic wand to enable pipette-free concentration of sample RNA and cell debris removal, 4) Quality control with a nasopharyngeal-specific mRNA target, and 5) Co-detection of other respiratory viruses, such as Influenza B, by duplexing QUASR-modified RT-LAMP primer sets. The flexible nature of the ALERT workflow allows easy, at-home and point-of-care testing for individuals and higher-throughput processing for centralized labs and hospitals. With minimal effort, SARS-CoV-2-specific primer sets can be swapped out for other targets to repurpose ALERT to detect other viruses, microorganisms or nucleic acid-based markers.

29 May 2026 in Science Advances
Verified
Journal Article
Open access
SSSeverino Jefferson Ribeiro da Silva
Severino Jefferson Ribeiro da Silva
QMQuinn Matthews
Quinn Matthews
SCSéverine Cazaux
Séverine Cazaux
JVJustin R. J. Vigar
Justin R. J. Vigar
BSBárbara N. R. Santos
Bárbara N. R. Santos
KPKeith Pardee
Keith Pardee
Limitations in global access to research and health care capacity undermine equity, sustainability, and resilience, particularly in resource-limited settings. Molecular diagnostics and biologic therapeutics are set to revolutionize medicine; however, our dependence on centralized biomanufacturing and cold chain logistics restricts access to these benefits. These constraints reflect a chronic and unmet global challenge. Here, with research teams in North and South America and Asia, we challenge the top-down paradigm by advancing community-driven solutions that empower underserved populations to participate in the bioeconomy, producing what they need, when, and where they need it. Our approach leverages low-burden biomanufacturing—built on cell-free protein synthesis and open-source hardware—to enable local, on-demand production of high-value bioproducts, including growth factors, vaccines, and diagnostic enzymes, demonstrating performance comparable to commercial gold standards. Implemented at 10 sites worldwide, this platform supported patient trials targeting globally relevant pathogens. Together, these efforts lay the foundation for a globally inclusive biomanufacturing ecosystem, where innovation goes beyond geographic boundaries.

3 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
FQFrancisco J. Quero
Francisco J. Quero
GAGuy Aidelberg
Guy Aidelberg
HVHortense Vielfaure
Hortense Vielfaure
YKYann Huon de Kermadec
Yann Huon de Kermadec
SCSeverine Cazaux
Severine Cazaux
ALAriel B. Lindner
Ariel B. Lindner
Access to affordable and reliable scientific instrumentation remains a significant barrier to the democratization of healthcare and scientific research. In the field of biotechnology, in particular, the complexity, cost, and infrastructure requirements of many instruments continue to limit their accessibility, especially in resource-limited environments. Despite the recent increase in the development of open-source tools, driven by advances in digital fabrication and electronic prototyping, few of these projects have reached large-scale implementation or validation in real-world settings. Here, we present qByte, an open-source, 8-tube isothermal fluorimeter designed to overcome these barriers by offering a cost-effective ($60) yet production-ready solution. qByte leverages standard digital manufacturing and Printed Circuit Board (PCB) assembly techniques and is designed to be portable, making it ideal for both laboratory and field use. The device has been benchmarked against commercial real-time thermocyclers and spectrophotometers, showing comparable results across four key applications: nucleic acid amplification and detection, analysis of protein activity and stability, genetic construct characterization, and bacterial viability tests. Further testing including the on-site diagnosis of human parasites in Kumasi, Ghana, and field work in Patagonia, Chile, validated qByte’s reliability in real-world conditions. Taken together, our results proved qByte as flexible and reliable equipment for a variety of biological tests and applications, while its affordability and open-source design simplify further development and allow adaptation to the needs of future users.

3 September 2020
Verified
Preprint
Open access
PDF file
MRMaira Rivera
Maira Rivera
SCSeverine Cazaux
Severine Cazaux
ACAriel Cerda
Ariel Cerda
AMAnibal Arce Medina
Anibal Arce Medina
INIsaac Núñez
Isaac Núñez
CRCesar A Ramirez-Sarmiento
Cesar A Ramirez-Sarmiento
This protocol has been optimized for the recombinant expression of a codon-optimized Bst-LF polymerase. The goal of this protocol was to eliminate the use of large volumes for dyalisis through the use of concentrators for buffer exchange before storage conditions. The plasmid encoding the codon-optimized Bst-LF enzyme used here can be found on reclone.org

13 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
DBDylan M. Brown
Dylan M. Brown
DPDaniel A. Phillips
Daniel A. Phillips
DGDavid C. Garcia
David C. Garcia
AAAnibal Arce
Anibal Arce
TLTyler Lucci
Tyler Lucci
JLJulius B. Lucks
Julius B. Lucks
Cell-free synthetic biology biosensors have potential as effective in vitro diagnostic technologies for the detection of chemical compounds such as toxins and human health biomarkers. They have several advantages over conventional laboratory-based diagnostic approaches, including being able to be assembled, freeze-dried, distributed, and then used at the point-of-need. This makes them an attractive platform for cheap and rapid chemical detection across the globe. Though promising, a major challenge is scaling up biosensor manufacturing to meet the needs of their multiple uses. Currently, cell-free biosensor assembly during lab-scale development is mostly performed manually by the operator, leading to quality control and performance variability issues. Here we explore the use of liquid handling robotics to manufacture cell-free biosensor reactions. We compare both manual and semi-automated reaction assembly approaches using the Opentrons OT-2 liquid handling platform on two different cell-free gene expression assay systems that constitutively produce colorimetric (LacZ) or fluorescent (GFP) signals. We test the designed protocol by constructing an entire 384-well plate of fluoride sensing cell-free biosensors and demonstrate that they perform closely to expected detection outcomes.